Characteristics of primary AML samples from quizartinib-sensitive and quizartinib-relapsed (bold) patients
| Sample . | Cytogenetics . | Cytogenetic risk group . | NPM1 mutation . | FLT3 mutation . | RUNX1 mutation . |
|---|---|---|---|---|---|
| AML-7 | Normal | Intermediate | Mutant | ITD | Not tested |
| AML-7 | Normal | Intermediate | Mutant | ITD | WT |
| AML-14 | t(6;9)(p23;q34.1) | Intermediate | WT | ITD | Not tested |
| AML-14 | t(6;9)(p23;q34.1) | Intermediate | WT | ITD, D835Y* D835del† | Not tested |
| AML-15 | +13 | Intermediate | WT | ITD | Not tested |
| AML-15 | +13 | Intermediate | WT | ITD D835_M837 delinsValLeu‡ | D93fs§ L110Q|| |
| Sample . | Cytogenetics . | Cytogenetic risk group . | NPM1 mutation . | FLT3 mutation . | RUNX1 mutation . |
|---|---|---|---|---|---|
| AML-7 | Normal | Intermediate | Mutant | ITD | Not tested |
| AML-7 | Normal | Intermediate | Mutant | ITD | WT |
| AML-14 | t(6;9)(p23;q34.1) | Intermediate | WT | ITD | Not tested |
| AML-14 | t(6;9)(p23;q34.1) | Intermediate | WT | ITD, D835Y* D835del† | Not tested |
| AML-15 | +13 | Intermediate | WT | ITD | Not tested |
| AML-15 | +13 | Intermediate | WT | ITD D835_M837 delinsValLeu‡ | D93fs§ L110Q|| |